Results 41 to 50 of about 1,439 (150)

Kikuchi-Fujimoto Disease Associated with Myasthenia Gravis: A Case Report

open access: yesCase Reports in Medicine, 2010
Kikuchi-Fujimoto disease is a self-limited benign condition of unknown etiology characterized by cervical lymphadenopathy, fever, and leucopenia. An autoimmune hypothesis has been suggested and an association with systemic lupus erythematosus, Sjogren's ...
Olukayode Onasanya   +4 more
doaj   +1 more source

Kikuchi-Fujimoto disease [PDF]

open access: yesLa Revue de medecine interne, 2011
Kikuchi-Fujimoto disease is a necrotizing lymphadenitis, involving young patients, predominantly females. Lymphadenopathy is usually localized, particularly in the cervical area, mostly unilateral and tender. Fever is present in one third of cases. Associated skin lesions, arthralgia, myalgia, splenomegaly or hepatomegaly are rare.
openaire   +3 more sources

Development of a Self‐Adjuvanting Influenza Peptide–Glycolipid Conjugate Inducing CD8+ T‐Cell Immunity

open access: yesChemBioChem, Volume 27, Issue 5, 13 March 2026.
The glycolipid‐peptide antigen complexes for self‐adjuvanting conjugates were successfully synthesized, and, with the HLA‐transgenic mice, the antigen‐specific CD8+ T cell expansion was exhibited. The results provide useful insights for the design and synthesis of vaccine conjugates using glycolipid antigen as an adjuvant.
Shunya Kikuchi   +4 more
wiley   +1 more source

A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab

open access: yesIJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Upper tract urothelial carcinoma with neuroendocrine differentiation (UC‐NE) is extremely rare and generally associated with aggressive behavior and poor prognosis. Optimal treatment strategies remain unclear, particularly regarding the role of nectin‐4–targeted therapy. Case Presentation A 61‐year‐old man was diagnosed with UC‐NE
Kosei Taniguchi   +9 more
wiley   +1 more source

Issue Information

open access: yes
Rheumatology &Autoimmunity, Volume 6, Issue 2, June 2026.
wiley   +3 more sources

Association of Immune‐Related Adverse Events and the Efficacy of Immune Checkpoint Inhibitors in Non‐Small Cell Lung Cancer: Adjusting for Immortal Time Bias

open access: yesThoracic Cancer, Volume 17, Issue 6, March 2026.
Immortal time bias (ITB)–adjusted landmark and time‐dependent Cox analyses showed that immune‐related adverse events (irAEs) were not associated with improved survival in NSCLC patients receiving first‐line immune checkpoint inhibitors. ECOG performance status remained the key prognostic factor.
Yoshiki Kuwabara   +20 more
wiley   +1 more source

Kikuchi–Fujimoto disease manifesting bilateral lymphadenopathy

open access: yesClinical Case Reports, 2022
Physicians should keep in mind that Kikuchi‐Fujimoto disease can show bilateral lymphadenopathy like the present case.
Akihiro Kawatsuki   +3 more
doaj   +1 more source

The Kikuchi-Fujimoto Disease in Nigeria: A Case Report and Literature Review

open access: yesCase Reports in Medicine, 2014
The Kikuchi-Fujimoto is a rare, self-limiting disease, which is characterized by regional lymphadenopathy. It occurs worldwide with a higher prevalence among Asians and women below the age of forty years.
Akinsegun Akinbami   +9 more
doaj   +1 more source

Kikuchi-Fujimoto disease: a case report and the evaluation of diagnostic procedures

open access: yesBMC Oral Health, 2019
Background Kikuchi-Fujimoto disease, known as histiocytic necrotizing lymphadenitis, is a benign, self-limiting and systemic disorder involving lymph nodes with unknown aetiology.
Shenjie Xu, Weilian Sun, Jiamei Liu
doaj   +1 more source

Novel Clinical and Histological Insights into Cutaneous Kikuchi‐Fujimoto Disease and Kikuchi Disease‐Like Inflammatory Pattern (KLIP)

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 7, Page e983-e987, July 2026.
Magí Brufau‐Cochs   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy